All patients included in the BENEFIT 15 study can be considered to have started treatment with BETAFERON relatively early in the course of the disease . (Patients originally allocated to placebo started therapy on average (SD) 1.5 (0.7) years after their first clinical event suggestive of MS .) At 15 years, there was no difference in disability between groups. Patients overall had relatively mild disability, with 79% of all patients experiencing no impairment to walking (EDSS ≤ 3.5) . Median EDSS increased from 1.5 at baseline to 2.0 at year 15 .
Furthermore, patients had a low risk of conversion to SPMS within 15 years: the Kaplan-Meier estimate of risk of secondary progressive MS (SPMS) was 10.2% overall .
Disability status of the patients included in the BENEFIT 15 study. Overall, the early BETAFERON treated patients experience relatively mild disability 15 years after disease onset 
EDSS: Expanded Disability Status Scale
SD: standard deviation
- Kappos L et al. American Academy of Neurology. Annual Meeting 2019, P3.2-080. Return to content